How can malignant tumors be more precisely visualized, characterized, and more effectively treated?
Some 500,000 people per year in Germany develop cancer for the first time. In order to advance the battle against cancer, it is important for researchers from diverse sectors, ranging from biology to chemistry and physics all the way to medicine, to cooperate with one another. Also relevant: The fast transfer of findings from basic research into clinical applications and back.
Cancer research at the HZDR focuses on several major fields: Specialized on Positron-Emission Tomography (PET), our scientists conduct research on new radioactive pharmaceuticals for the diagnosis of cancer and improve medical imaging technology. They also investigate new ways to target cancer cells with the body's own immune system and they also use radiactive drugs to irradiate tumor tissue from within the body. Additionally, our researchers develop compact and cost-efficent accelerator technology for proton therapy and find innovative methods to monitor the proton beams in real-time.
- Developing radioactive substances for research, diagnosis, and therapy
- Planning of individualized radiation treatment
- Monitoring radiation in real time
- Developing the radiation therapy systems of tomorrow
- Molecular Spies to Fight Cancer
- Tracking down the beam
- Visualizing Protein Scissors inside Tumors
- In the fight against cancer the HZDR cooperates closely with the University Hospital Dresden and the Technische Universität Dresden in the jointly organized OncoRay center. Together with the Heidelberg Institute of Radiation Oncology OncoRay constitutes the "National Center for Radiation Research in Oncology Dresden / Heidelberg"
- With their research HZDR scientists also support the University Cancer Center Dresden, a facility of the University Hospital and the Technical University of Dresden
- HZDR, University Hospital and TU Dresden have established the Universitäts ProtonenTherapie Dresden and continue to improve the technology for this new radiation therapy
- The three Institutes are also united in a consortium, which builds up Dresden as a partner site of the National Center for Tumor Diseases (NCT). They also constitute – together with the Max Planck Institute of Molecular Cell Biology and Genetics – the Partner Site Dresden of the German Consortium for Translational Cancer Research.
Research on Brain Diseases
The main focus of research conducted within the Division of Neuroradiopharmaceuticals at the HZDR’s research site in Leipzig, Germany, is the early diagnosis of brain diseases like Alzheimer’s, dementia, or brain cancer. In collaboration with the Faculty of Medicine as well as the Faculty of Pharmacy at Leipzig University the scientists develop radioactive molecular probes for the investigation of cancer-related cognitive defects.